In this controlled study, we aimed to evaluate the sexual dysfunction of patients with polycystic ovary syndrome (PCOS) in comparison to healthy controls. We enrolled 64 sexually active women in our study. The PCOS group consisted of 32 women who met the Rotterdam diagnostic criteria, and the control group was composed of 32 age-matched, healthy females. In addition to the demographic and clinical characteristics of the participants, the hormonal and biochemical parameters were also studied. All patients were invited to fill out the female sexual function index (FSFI) and Beck's Depression Inventory questionnaires. The prevalence of sexual dysfunction in the PCOS group was similar to controls (25% vs 19%; P ¼ 0.54). No significant difference was found according to each domain score of FSFI. Significant negative correlations were found between the total FSFI scores of the PCOS group and the total (r ¼ À 0.278) and free testosterone (r ¼ À 0.493) levels. Although depressive scores of PCOS patients were higher, they did not show greater impaired sexual functions than age-matched controls according to their FSFI scores. Considering the multifactorial state of female sexual dysfunction, further studies are needed to clarify the impact of PCOS upon sexuality.
INTRODUCTION
Polycystic ovary syndrome (PCOS) is an endocrine disorder that reflects multiple potential etiologies and variable clinical presentations in women of reproductive age. The prevalence of the condition is estimated to be between 4 and 25% depending upon the definitions used for diagnosis. [1] [2] [3] PCOS manifestations include irregular menstrual cycles and polycystic ovaries in conjunction with hirsutism and/or acne; obesity is also frequently concomitant. 4 Female sexual dysfunction (FSD) is influenced by medical and psychosocial factors, and the condition has become a common and important health concern in recent years. [5] [6] [7] [8] [9] Sexual problems are highly prevalent in women; according to one report, B40% of women have sexual concerns, in which 12% experience distressing sexual problems. 10 Sexuality includes selfimage, partnership, activity, behavior, attitudes and function. 11 Traditionally, FSD has included disorders of desire/libido, arousal, sexual pain/discomfort and inhibited orgasm. 12 Organic and psychogenic issues are both involved in the etiology of FSD. 13 Although there may be a genetic susceptibility, 14 many biological, cognitive, emotional, and social factors seem to exert a relevant influence on sexual response and enjoyment. 12, 13, 15, 16 Alterations in the physical appareance of patients and changes in sexual hormones may lead to psychological distress in patients, which usually results in a loss of quality of life and may affect sexuality. 17, 18 Several features of PCOS might have potential affects on sexual health. Women with PCOS ovulate infrequently and therefore experience an ovulatory infertility, 19 which has been linked to decreased sexual satisfaction. 20, 21 A negative influence on sexuality in PCOS may be due to changes in self-image from syndrome-related hirsutism and/or acne, 22, 23 whereas high androgen levels due to PCOS may or may not have beneficial sexual effects. [24] [25] [26] [27] [28] Obesity is another important clinical manifestation of PCOS that has been associated with decreased sexual satisfaction but not with decreased sexual activity. 29 We aimed to evaluate the sexual function of PCOS patients in comparison with healthy controls. Our hypotheses was that PCOS patients could improve their sexuality due to their high androgen levels or PCOS could exhibit a negative impact on sexuality due to changes in self-image.
MATERIALS AND METHODS

Study population
This controlled study was conducted using data gathered from two university hospitals' gynecology departments. The study was approved by the Institutional Review Board of Gulhane School of Medicine, and all women who took part gave written informed consent before enrolling in the study. All participants were of Caucasian descent and socially homogeneous. We included 64 otherwise healthy women who were faithfully married with an active sexual life. The study group consisted of 32 women with the diagnosis of PCOS, and the control group contained 32 age-matched, healthy, regularly menstruating, non-PCOS women who were admitted to our outpatient unit for a routine check-up within the same study interval.
The health status of the participants was determined on the basis of a detailed medical history, blood chemistry tests and a comprehensive gynecological examination by the same physician (HC) (including transvaginal ultrasound) at their initial visits to detect any genital abnormality, infection, adnexal mass, atrophy or pelvic floor insufficiency. Hypothalamo-pituitary-gonadal axis functional integrity was examined via hormonal measurements of the participants. Revised Rotterdam diagnostic criteria were used to diagnose PCOS in patients who had two out of the three following features: Oligo-and/or anovulation, clinical and/or biochemical signs of hyperandrogenism and polycystic ovaries (the presence of 12 or more follicles of 2-9 mm in diameter and/or an ovarian volume greater than 10 cm 3 ) visualized on ultrasound. 30 The inclusion criteria of the study were women who were married, sexually active and between the ages of 20 and 40 who had at least a secondary school education, agreed to fill out the Female Sexual Function Index (FSFI) and Beck's Depression Inventory (BDI) questionnaire forms, and gave informed consent for participation.
Women were excluded from the study if they had any of the following: pregnancy, a postpartum period within the past 3 months, gynecologic disorders that might affect female sexual function (that is, pelvic floor disorders, adnexal mass or atrophy, endometriosis), a history of psychological disorders (that is, anxiety states, obsessive-compulsive disorders, vaginismus), a history of internal pathology (that is, hepatic, pulmonary, renal, hematological, or endocrine diseases such as diabetes mellitus, prolactinoma or thyroid dysfunction), menopausal symptoms (including menstrual irregularities or permanent cessation of menses), and no regular sexual intercourse, which was defined as any woman who was not with her husband during the study period. Moreover, patients who did not want to complete the questionnaire forms and patients receiving any medication up to 3 months before the study that could interfere with sexual function (that is, oral contraceptives, estrogens, anti-androgens, sedatives, antidepressants, antidiabetic medications and beta blockers) were excluded due to their possible confounding effects.
Measures
Initially, the demographic data and clinical characteristics (including age, obstetric history, body mass index, and modified Ferriman-Gallwey scores) of PCOS patients and controls were recorded. The body mass index was calculated as weight in kilograms divided by the square of height in meters. Hirsutism was evaluated by the Ferriman-Gallwey scoring system, where a woman with a total score of X8 was considered to be hirsute. 31, 32 Venous blood samples were collected in the morning after a 12-h fasting period during the early follicular phase (2nd to 5th days of menses) of the patients' menstrual cycles. The laboratory assays were performed in accordance with the protocol reported in the study of Yildirim et al. 33 in which the researchers had studied the relationship between intraabdominal fat distribution and metabolic disorders in PCOS patients. The measured hormonal and biochemical parameters of the study and control groups were follicle stimulating hormone, luteinizing hormone (LH), LH/ follicle stimulating hormone ratio, estradiol, total testosterone (TT), free testosterone (fT), prolactin, thyroid stimulating hormone, and fasting glucose and insulin levels. The estimate of insulin resistance was calculated using the homeostasis model for insulin resistance index (HOMA-IR): Fasting glucose (mg dl À 1 ) Â fasting insulin (mIU ml À 1 )/405. 34 Plasma TT levels were determined using the chemiluminescence method (ADVIA Centaur XP Immunoassay System, Siemens, Tarrytown, NY, USA) (sensitivity: (minimum detectable concentration) 10 ng dl À 1 , Intra CV: o6.2% and Inter CV: o4.7%). Plasma fT levels were assessed by the radioimmunoassay method (Active Free testosterone RIA kit, Catalog No. DSL 4900, Beckman Colter, Brea, CA, USA) (sensitivity: (minimum detectable concentration) 0.18 pg ml À 1 , Intra CV: o6.5% and Inter CV: o9.7%).
All participants were invited to fill out the FSFI and BDI questionnaires, 12, 35 which upon completion would be placed in a sealed envelope under the supervision of a nurse. Patients were assured that their information would remain confidential and that their refusal to take part in the study would not affect their care and treatment.
The FSFI is a validated, 19-item self-report that evaluates the sexual function of women within a 4-week window. The Turkish version of the FSFI is reliable and has been validated for the Turkish population. 36 Sexual dysfunction was defined as a total FSFI score of less than 26. 37 Specific domains analyzed by the FSFI are sexual desire (questions 1 and 2), arousal (questions 3 to 6), lubrication (questions 7 to 10), orgasm (questions 11 to 13), satisfaction (questions 14 to 16) and degree of pain (questions 17 to 19). The maximum score of each subscale is 6, and the maximum total score is 36. Higher scores indicate better function, whereas a domain score of zero indicates no sexual activity during the past month. Each domain score and the overall FSFI scores of participants with PCOS and also of controls were compared.
The BDI adapted to a Turkish population 38 was first developed by Beck et al. 35 and is a widely used screening tool to identify the presence of psychologic depression. BDI is a self-report scale with 21 items that measure the emotional, somatic, cognitive and motivational symptoms seen in depression. The aim of this scale is not to diagnose depression but instead to objectively determine the severity of depressive symptoms. Using this inventory, the patient rates the intensity of the items on a 4-point scale (0-3) in which the depression score is obtained by adding the scores for each item. The highest score obtainable is 63. BDI scores X17 have been reported to identify depression that might require treatment with a 490% accuracy. 39 
Statistical analysis
The Statistical Package for the Social Sciences (SPSS), version 15.0 (SPSS, Chicago, IL, USA), was used for our statistical analysis. Data were expressed as mean ± s.d. Descriptive statistics were computed for PCOS and control participants and compared using an unpaired student's t-test for continuous data. The w 2 -test was used for comparing proportions. A power analysis was calculated as 85% with an alpha of 0.05. The Pearson correlation index was used to analyze the relationship between the total FSFI scores and other variables in the study. A P-value of o0.05 was considered to be statistically significant.
RESULTS
Sixty-four out of the 69 women who initially presented were enrolled to the study. Two out of 34 PCOS patients and 3 out of 35 controls who had similar demographic parameters and hirsutism scores compatible with their groups were excluded from the data because they did not complete the FSFI questionnaires. The mean age of all participants was 27.2±3.2 years. The mean ages of the PCOS group and the healthy controls were similar. Although the mean body mass index of PCOS patients were higher than the controls, the difference was not statistically significant. As expected, Ferriman-Gallwey scores of the PCOS patients were significantly higher than the controls (12.9 ± 5.1 vs 5.7 ± 3.9; Po0.001). None of the controls complained about acne vulgaris, whereas 14/32 (43.7%) of the PCOS participants suffered from acne. The two groups were similar with regard to the participants' parity and demographic features (education status, duration of marriage, income level and occupation) (P40.05); only the mean husbands' age of the control group was higher than the PCOS participants. (33.8 ± 6.1 vs 30.7 ± 4.8; Po0.05) ( Table 1) .
The hormonal and biochemical profiles of the study groups are shown in Table 2 . Briefly, LH, TT, fT and fasting insulin levels were significantly higher in the PCOS patients than in the controls (Po0.05). There were no significant differences between PCOS patients and healthy controls according to follicle stimulating hormone, estradiol, prolactin, thyroid stimulating hormone and fasting glucose levels. HOMA-IR levels were significantly higher in the PCOS group than in the controls (2.5 ± 0.7 vs 2.0 ± 0.5; Po0.05).
Fourteen of 64 (22%) women in the study were diagnosed with sexual dysfunction. The prevalence of sexual dysfunction in the PCOS group (8/32; 25%) was similar to that in controls (6/32; 19%) without a statistically significant difference (P ¼ 0.54). The FSFI and BDI questionnaire scores are shown in Table 3 . No history of major depression was recorded in either group according to their medical histories. No significant difference was found based on each domain score of FSFI testing (desire, arousal, lubrication, orgasm, pain and satisfaction). Although the desire domain mean value was higher in the PCOS group than in the controls, the difference was not statistically significant (4.9 ± 1.1 vs 4.3 ± 1.2; P40.05). In the covariance analysis, no statistically significant difference was identified between the PCOS and control groups even after an adjustment by LH, TT, fT, fasting insulin, and HOMA-IR levels.
In the correlation analysis, no relationship was found between the total FSFI scores of the PCOS group and body mass index, follicle stimulating hormone, estradiol, prolactin, thyroid stimulating hormone and fasting glucose levels. However, significant negative correlations were noted between the total FSFI scores of PCOS patients and their LH (r ¼ À 0.414, P ¼ 0. Table 4) .
DISCUSSION
In recent years, there has been a growing interest in the impact of PCOS upon the health-related quality of life of women who suffer from the condition. As there is currently no cure for PCOS, management is aimed at symptomatic alleviation and prevention of long-term complications. 40 As quality of life is important, we focused on assessing the sexual functioning of PCOS patients in comparison with controls. Although sexual problems can be related to both partners, they are more prevalent for women (43%) than men (31%). 5, 41 FSD takes different forms, including lack of sexual desire, impaired arousal, inability to achieve orgasm or pain with sexual activity. 42, 43 Within this scope, the FSFI is one of the most powerful self-reporting instrument as a standardized, validated sexual inventory for assessing the key dimensions of sexual function in women. 44 In the United States, sexual problems associated with personal distress are statistically significant, but are only reported in B12% of women. 10 Hence, distress scales (that is, female sexual distress scale) are often used to augment the assessment of FSD in measuring a woman's feelings concerning distress about her sex life. 10 However, we only used FSFI scoring in the scope of our study.
In PCOS, irregular menses and infertility issues have been suggested to cause tensions within the family, altered selfperception, impaired sexual functioning and problems in the workplace. 40, 45 Another negative influence on sexuality in PCOS may be due to the changes in body appereance from PCOSrelated hirsutism, acne and/or obesity in these patients, the perceived 'unattractiveness' of these symptoms induces depression and a loss of feminine identity and also can limit a Income levels classified according to poor p800, moderate 800-1500, good X1500 US $ per month. 
Sexual dysfunction in PCOS CM Ercan et al
woman's emotional well-being and quality of life. 18, 46 Moreover, a diagnosis of PCOS itself has been found to be associated with feelings of frustration and anxiety, 47 which could also lead to FSD. Rasgon et al. 48 reported that insulin resistance and obesity are associated with depression in PCOS. In addition, obesity can profoundly affect the quality of life and induce depression independently from other clinical symptoms in otherwise healthy people. 18, 49 Although PCOS participants in the present study could not be categorized as overweight, their insulin resistance was obvious as shown by the hyperinsulinemic state and HOMA-IR levels.
Desire and arousal disorders are the most frequently reported female sexual problems in the literature. 8, 50 In our study we assessed female sexual function only by FSFI scoring system and low sexual function was determined in 22% of our entire study group based on the cutoff FSFI score of 26 or less. The most significantly influenced domains in these participants were in line with the results of Aslan et al. 50 , desire and arousal, followed by orgasm, satisfaction and pain disorders, respectively. Notable hormonal alterations in PCOS patients were documented in our study, but no statistical correlations were detected between hormonal status and sexual function, except for TT, fT, insulin and LH levels. Although a relatively small study population size and/or a bias of sampling of PCOS women with a milder disorder might have influenced our findings, the results of our study confirmed the data of Veras et al. 17 , where the researchers studied the sexual function of patients with PCOS and reported a negative correlation between the scores of Arizona Sexual Experience Scale and the levels of TT, LH and dehydroepiandrosterone sulfate. The possible meaning of the negative correlation between sexual function and androgen levels (verified in our study and the study by Veras et al.) might be linked to hirsutism, acne vulgaris and subsequent poor body image, leading to esthetic problems and may affect the psychosexuality of PCOS patients. However, the common results obtained from both studies did not confirm this hypothesis; no impairement in sexual function was shown in patients with PCOS. Veras et al. even suggested that in patients with PCOS, despite the esthetic and reproductive factors related to high T levels, hyperandrogenism could act as a protecting factor for the aspects related to sexual function. 17 We performed a covariance analysis by adjusting for hormone levels to find the effect of PCOS on FSFI scores, and we noted no significant difference between the two groups. However, the high degree of interaction of biological and psychological systems limits the generalizability of our results to the entire PCOS population.
All FSFI domain scores in our PCOS group were lower than those of the controls, except for the desire domain, which was slightly but not significantly higher. It is complex to show the impact of hormones on sexual function because limited research data are available. Though we could not prove this hypothesis, high testosterone levels could be associated with increased sexual desire, which may be the subject of future studies in PCOS patients. The role of androgens in female sexual function is still in question. 43 In recent studies, serum levels of testosterone have not been shown to correlate with women's sexual function. [51] [52] [53] In naturally menopausal women with hypoactive sexual desire disorder, transdermal testosterone patch therapy was effective in improving sexual function. 25 However, more recently Basson et al. 54 did not identify reduced androgen activity in women with hypoactive sexual desire disorder or in women with hypoactive sexual desire disorder plus the concomitant inability to experience a satisfying sexual response in comparison with sexually healthy controls. In addition, while women have lower ovarian androgen levels after surgical vs natural menopause, no significant change in sexual function was reported in the following 1-3 years when women electively chose bilateral oophorectomy along with their hysterectomies. [55] [56] [57] Our study supports these findings in that women with high androgen levels due to PCOS (a natural biological model) do not exhibit any beneficial sexual effects when compared with controls. The negative result reached in our study should not be interpreted as evidence of no FSD in PCOS patients, especially due to our relatively small sample size. Our results are in line with some of the previous studies, 17, 49 whereas a more recent study reported that PCOS patients experienced decreased satisfaction with their sex lives. 21 Additionally, Battaglia et al. 49 reported that moderate hirsutism and hyperandrogenism do not induce a sense of loss of a feminine identity and have no impact on sexual selfworth and sexual satisfaction. However, de Niet et al. 62 found that clinical characteristics such as hyperandrogenism and acne were associated with poorer body satisfaction in PCOS patients. The hirsutism rate reported in the general population (4.6 to 10%) may differ according to populations and regions. 32, 58 For example, in Mediterranean countries, the distribution of body hair in women is denser than that of other populations. 32 In Turkey, a Mediterranean country, the upper lip had the highest score as an androgen-sensitive area of the body; Ferriman-Gallwey scores equal to 8 or less were reported in 68% of the Turkish population. 59 A recent trial conducted in the southeastern part of Turkey 60 found a hirsutism ratio of 15%, which provides clear evidence for the difference between regions of the same country; this rate was as high as that seen in our PCOS patients.
Sexuality attitudes and behaviors are influenced by family, society and culture to a great extent. Therefore, when discussing any related topic about sexuality, it is important to know the basic features and socio-cultural context of the studied population. In Turkish culture, premarital female virginity is considered to be an important social norm that is linked to the concept of sexual purity. Today in Turkey, there is relative autonomy in the management of young people's affairs, including marital decisions. Male-female relations are less closely controlled, and western-style dating is common, especially in cities, which are where 70% of the Turkish population now lives. 61 Thus, in the present study, we did not question the arranged marriages of participants, which may be associated with sexual dysfunction themselves (regardless of PCOS) and could, therefore, lead to a limitation of our study.
Women with PCOS and amenorrhea have lower levels of selfesteem, greater fears of negative appearance evaluations and an earlier age of sexarche. 62 A study comparing adolescents who have PCOS with healthy controls concluded that PCOS patients are more concerned about fertility, which could affect their overall quality of life. This study found no difference between groups regarding sexual function except that healthy participants were 2.8 times more likely to have had sexual intercourse than PCOS participants. 63 Although the absence of fertility issues among the PCOS participants in our study could be considered a deficiency, we found no significant difference between our control and PCOS groups according to their gravidity and parity.
The limitations of our study are; first, the study was performed with a relatively small sample size in a Muslim community. In Turkey, there is a strong effect of family, society and religion on sexual attitudes and behaviors, yet sexuality cannot be discussed openly in many regions. Premarital sexual experiences are very limited, particularly among young women who were raised with traditional values; sexual relations outside of marriage are also not well-tolerated. In our study, we received a positive response to the given surveys from the participants (64/69, 93%), mainly because of the higher socio-cultural levels of the patients who receive care at our institution.
Second, our study groups were not overtly obese, which could have protected them from developing negative body images and subsequent FSD. Third, we did not employ either of the two commonly used measures of acne vulgaris (granding and lesion counting) to assess the participants' acne status. Finally, we only assessed women who were 'sexually active'. As in this and other similar studies, women with sexual dysfunctions that preclude sexual activity and partnered sexual activity in particular did not get studied. Therefore, if a syndrome or disease seriously impacts sexual function to the point of no activity or no partnered activity, these women will never be studied because our inclusion criteria only called for sexually active women. Owing to these reasons, our findings should not be generalized to the entire PCOS population before larger studies with more supporting evidence are published.
The data of the present study showed that women with PCOS did not exhibit impaired sexuality anymore than age-matched controls according to their FSFI scores. Our results indicated that high testosterone levels did not produce beneficial effects on sexual function in PCOS patients. Although this result might be due to esthetic concerns, it was an interesting finding as testosterone has been suggested as a possible treatment of FSD. However, the absence of a positive result in the present study should not be interpreted as proof of its absence, as sexual function is strongly affected by relationships and socio-cultural factors in additon to physiological and psychological problems. Therefore, further multicenter studies with larger study groups and that include different cultures and ethnicities will be required to clarify and understand the impact of PCOS upon sexuality.
